Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis

Lung Cancer

Volumn 77, Issue 3, 2012, Pages 572-577

  Bae, Hyun Mi ^a,b   Lee, Se Hoon ^a   Kim, Tae Min ^a   Kim, Dong Wan ^a   Yang, Seok Chul ^a   Wu, Hong Gyun ^a   Kim, Young Whan ^a   Heo, Dae Seog ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Bupyeong gu   (South Korea)

Author keywords

Bone metastasis; NSCLC; Prognostic factor; Skeletal related events

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PAIN; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SPINAL CORD COMPRESSION; SPINE FRACTURE;

ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84865174333     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.05.094     Document Type: Article

References (22)

1. Rosen L.S., Gordon D., Tchekmedyian N.S., Yanagihara R., Hirsh V., Krzakowski M., et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 2004, 100:2613-2621.
2. Price N. Bisphosphonates to prevent skeletal morbidity in patients with lung cancer with bone metastases. Clin Lung Cancer 2004, 5:267-269.
3. Delea T.E., McKiernan J., Brandman J., Edelsberg J., Sung J., Raut M., et al. Impact of skeletal complications on total medical care costs among patients with bone metastases of lung cancer. J Thorac Oncol 2006, 1:571-576.
4. Han S.W., Kim T.Y., Hwang P.G., Jeong S., Kim J., Choi I.S., et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005, 23:2493-2501.
5. Thatcher N., Chang A., Parikh P., Rodrigues Pereira J., Ciuleanu T., von Pawel J., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005, 366:1527-1537.
6. Langer C., Hirsh V. Skeletal morbidity in lung cancer patients with bone metastases: demonstrating the need for early diagnosis and treatment with bisphosphonates. Lung Cancer 2010, 67:4-11.
7. Coleman R.E., Smith P., Rubens R.D. Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer 1998, 77:336-340.
8. Eisenberger M.A., Crawford E.D., Wolf M., Blumenstein B., McLeod D.G., Benson R., et al. Prognostic factors in stage D2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT, 0036). The National Cancer Institute Intergroup Study #0036. Semin Oncol 1994, 21:613-619.
9. Fan K., Peng C.F. Predicting the probability of bone metastasis through histological grading of prostate carcinoma: a retrospective correlative analysis of 81 autopsy cases with antemortem transurethral resection specimen. J Urol 1983, 130:708-711.
10. Dinse G.E., Lagakos S.W. Nonparametric estimation of lifetime and disease onset distributions from incomplete observations. Biometrics 1982, 38:921-932.
11. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966, 50:163-170.
12. Chow E., Fung K., Panzarella T., Bezjak A., Danjoux C., Tannock I. A predictive model for survival in metastatic cancer patients attending an outpatient palliative radiotherapy clinic. Int J Radiat Oncol Biol Phys 2002, 53:1291-1302.
13. van der Linden Y.M., Steenland E., van Houwelingen H.C., Post W.J., Oei B., Marijnen C.A., et al. Patients with a favourable prognosis are equally palliated with single and multiple fraction radiotherapy: results on survival in the Dutch Bone Metastasis Study. Radiother Oncol 2006, 78:245-253.
14. van der Linden Y.M., Steenland E., van Houwelingen H.C., Post W.J., Oei B., Marijnen C.A. Prognostic factors for local control and survival after radiotherapy of metastatic spinal cord compression. J Clin Oncol 2006, 24:3388-3393.
15. Koizumi M., Yoshimoto M., Kasumi F., Ogata E. Comparison between solitary and multiple skeletal metastatic lesions of breast cancer patients. Ann Oncol 2003, 14:1234-1240.
16. Hirano Y., Oda M., Tsunezuka Y., Ishikawa N., Watanabe G. Long-term survival cases of lung cancer presented as solitary bone metastasis. Ann Thorac Cardiovasc Surg 2005, 11:401-404.
17. Zukawa M., Nakano M., Hirano N., Mizuhashi K., Kanamori M. The effectiveness of gefitinib on spinal metastases of lung cancer. Asian Spine J 2008, 2(2):109-113.
18. Sun J.M., Ahn J.S., Lee S., Kim J.A., Lee J., Park Y.H., et al. Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases. Lung Cancer 2011, 71:89-93.
19. Normanno N., De Luca A., Aldinucci D., Maiello M.R., Mancino M., D'Antonio A., et al. Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis. Endocr Relat Cancer 2005, 12:471-482.
20. Zhu J., Jia X., Xiao G., Kang Y., Partridge N.C., Qin L. EGF-like ligands stimulate osteoclastogenesis by regulating expression of osteoclast regulatory factors by osteoblasts: implications for osteolytic bone metastases. J Biol Chem 2007, 282:26656-26664.
21. Guise T.A., Mundy G.R. Cancer and bone. Endocr Rev 1998, 19:18-54.
22. Nemeth J.A., Yousif R., Herzog M., Che M., Upadhyay J., Shekarriz B., et al. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J Natl Cancer Inst 2002, 94:17-25.